CMS's current inclusion of noncovered self-administered drug prices in Medicare Part B payment calculations inflates costs for Stelara biosimilars. OIG recommends revising pricing methodology to achieve savings.
OIG report identifies Medicare overpayments for continuous glucose monitors and urges CMS to reduce payment rates, highlighting potential savings.
A recent OIG audit identifies $4.7 million in Medicare overpayments to optometrists for nursing home services due to insufficient CMS review processes and billing controls. The report urges enhanced oversight and provider training to prevent future improper payments.
The HHS OIG report reveals Medicare Part B overpayments for continuous glucose monitors and supplies, recommending rate reductions to align with supplier costs and enhance program efficiency.
OIG finds nursing homes underreporting major injury falls affecting accuracy of CMS Care Compare data; CMS to enhance compliance and reporting measures.
The HHS Office of Inspector General identifies $17 billion in potential cost savings by improving program efficiency and compliance in healthcare programs.
